The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Doxepin is a highly potent antihistamine, with this being its strongest activity. In fact, doxepin has been said to be the most or one of the most potent H1 receptor antagonists available, with one study finding an in vitro Ki of 0.17 nM. It is the most potent and selective H1 receptor antagonist of the TCAs (although the tetracyclic antidepressant (TeCA) mirtazapine is slightly more potent), and other sedating antihistamines, for instance the over-the-counter diphenhydramine (Ki = 16 nM) and doxylamine (Ki = 42 nM), show far lower affinities for this receptor in comparison. The affinity of doxepin for the H1 receptor is far greater than its affinity for other sites, and 10- to 100-fold higher doses are needed for antidepressant effects. In accordance, although it is often described as a "dirty drug" due to its highly promiscuous binding profile, doxepin acts as a highly selective antagonist of the H1 receptor at very low doses (less than 10 mg; typically 3 to 6 mg). At these doses, it notably has no clinically relevant anticholinergic effects such as dry mouth or cognitive/memory impairment, unlike most other sedating antihistamines, and similarly has no effect on other receptors such as adrenergic and serotonin receptors. The H1 receptor antagonism of doxepin is responsible for its hypnotic effects and its effectiveness in the treatment of insomnia at low doses.
On May 23, 2017, Duterte was in his first state visit to Russia, where he met Russian president Vladimir Putin to realign the Philippines's foreign policy away from the United States; among his top priorities in the trip included the acquisition of Russian-made munitions to use against Islamic militants in restive Mindanao. At that time, the Philippine military was in an operation to capture ASG leader Isnilon Hapilon. Duterte cut short his trip and flew back to the Philippines after the Maute Group, which pledged allegiance to the ISIS, occupied the city of Marawi in Lanao del Sur. Upon returning, Duterte declared Martial law across Mindanao and ordered a major offensive on the city to retake it. The battle, which lasted for five months, became the country's longest urban warfare; the city, particularly the downtown area, was left in ruins, largely due to militant fire and military airstrikes, necessitating rehabilitation. Hapilon and Omar Maute were eventually killed, and on October 17, Duterte declared the city liberated from terrorist influence. Citing the danger posed by Islamic terrorists, Congress, upon Duterte's requests, thrice granted the extension of martial law in Mindanao between 2017 and 2019. The moves drew criticism, particularly from rights groups, who claimed that the extensions were part of a campaign on stifling dissent. By the end of 2019, martial law in Mindanao lapsed, after which Duterte decided not to have it extended.
crest as well as on shirts sold by Wrexham's brick and mortar and virtual fan stores, the partnership ended in 2023 when Wrexham was promoted to the EFL League Two after which US airline United took over the partnership/sponsorship. On 8 January 2026, TikTok announced a new partnership with the FIFA World Cup. In early 2026, the United States and China approved a deal transferring operational control of TikTok's US business to a joint venture led by Oracle and Silver Lake, following a 2024 US law requiring ByteDance to divest the platform over national security concerns. Shou Chew announced in a memo addressed to employees that TikTok will henceforth operate in the United States under a joint investment entity in which the majority ownership will be American. Under the agreement reached, it is guaranteed that Americans will be protected on the social network TikTok through "data protection", "content oversight", and "algorithm security." In April 2026, TikTok partnered with ACRCloud to enhance its SoundOn platform with audio recognition technology aimed at identifying unauthorized or altered uses of copyrighted music. In June 2026, TikTok and Strava launched a joint initiative to support local sports communities across Europe by providing funding and promotional resources to selected creators and community organizations. In July 2026, TikTok announced a multi-year partnership with the NBA and WNBA, expanding access to exclusive content and interactive experiences for basketball fans within the platform.
Going back more than 350 years, the first landmark description was of general blood circulation by William Harvey in 1628, which formed the anatomical basis for intravenous infusions. Investigations during the following centuries demonstrated solutions containing electrolytes and glucose could be given intravenously. The accumulated knowledge of protein metabolism formed the basis for studies on intravenous nutrition with protein hydrolysates, peptides, and amino acids. Robert Elman's observation in the late 1930s that amino acids in the form of protein hydrolysate could be administered safely was the first major step toward TPN. During the following years, major efforts were made to find methods to prepare infusion solutions with a high energy content and low osmotic pressure. The most realistic alternative seemed to be fat in the form of an emulsion. Many studies of a large number of various fat emulsions were made from the 1920s until the end of the 1950s. However, all of these emulsions caused severe adverse reactions. The first safe fat emulsion, Intralipid, developed by Prof. Arvid Wretlind of the Karolinska Institute, Sweden, was made available for clinical use in 1962. This was the second major step toward TPN. Vitamins, electrolytes, and trace elements were then included in the fat emulsions and in the solutions of amino acids and glucose. Later in the 1960s, Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr.
Sources: en.wikipedia.org
738 Other acquired deformity 738.0 Acquired deformity of nose 738.1 Other acquired deformity of head 738.2 Acquired deformity of neck 738.3 Acquired deformity of chest and rib 738.4 Acquired spondylolisthesis 738.5 Other acquired deformity of back or spine 738.6 Acquired deformity of pelvis 738.7 Cauliflower ear 738.8 Acquired deformity of other specified site 738.9 Acquired deformity of unspecified site 739 Nonallopathic lesions, not elsewhere classified
=== Applications in semiconductor industry === UPW is used extensively in the semiconductor industry where the highest grade of purity is required. The use of UPW varies; it may be used to rinse the wafer after application of chemicals, to dilute the chemicals themselves, in optics systems for immersion photolithography, or as make-up to cooling fluid in some critical applications. UPW is even sometimes used as a humidification source for the cleanroom environment. The primary, and most critical, application of UPW is in wafer cleaning in and after wet etching step during the FEOL stage. Impurities which can cause product contamination or impact process efficiency (e.g. etch rate) must be removed from the water during cleaning and etching stage. In chemical-mechanical polishing processes, water is used in addition to reagents and abrasive particles. As of 2002 1-2 parts of contaminating molecules per one million of water ones was considered to be an "ultrapure water" (e.g. semiconductor grade).
"A lot of work has been done on all sorts of different scripts actually. So Mega-City One the TV show." He added. "Basically we can't go into production because of the [coronavirus pandemic] and we've got scripts and everything is ready to go but the problem is, because of the pandemic and everybody's funding changes and everybody's shifting around". In 2025, it was reported that a new Judge Dredd film was in development. It is set to be directed by Taika Waititi with a script by Drew Pearce.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.